Pharmaceutical

Chugai Pharmaceutical (TOKYO:4519) announced today that the U.S. Food and Drugs Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) and granted Priority Review for HEMLIBRA® [US generic name: emicizumab-kxwh] for adults and children with hemophilia A without factor VIII inhibitors. The FDA is expected to make a decision on approval by 4 October, 2018. …

Chugai Pharmaceutical (TOKYO:4519) announced today that the U.S. Food and Drugs Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) and granted Priority Review for HEMLIBRA® [US generic name: emicizumab-kxwh] for adults and children with hemophilia A without factor VIII inhibitors. The FDA is expected to make a decision on approval by 4 October, 2018.

As quoted in the press release:

“We are very proud that HEMLIBRA has been granted a second Priority Review for hemophilia A without inhibitors following the previous designation for hemophilia A with inhibitors, which underscores the innovation of this drug,” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Yasushi Ito. “In treatment of hemophilia A without inhibitors, there still remain unmet medical needs in the management of bleeding. Given this Priority Review status, we hope to be able to contribute to people with hemophilia A and their caregivers as soon as possible by providing HEMLIBRA as a new treatment option that can be administered subcutaneously with good bleeding control and eased treatment burden.”

The sBLA filing and Priority Review are based on the results of HAVEN 3 study (NCT02847637), which has been conducted with adults and adolescents with hemophilia A without factor VIII inhibitors under a collaboration between Chugai, Roche and Genentech. In EU, Roche has already filed the results to the European Medicines Agency for a supplemental indication of hemophilia A without inhibitors.

Click here to read the full press release.

MARKETS

Markets
TSX19270.85+128.13
TSXV632.02+4.88
DOW31318.44-337.98
S&P 5003924.26-42.59
NASD11630.86-154.26
ASX6965.50-138.60

COMMODITIES

Commodities
Gold1712.50+0.90
Silver18.06+0.01
Copper3.40-0.01
Palladium2024.65+11.78
Platinum839.21+4.21
Oil87.25+0.64
Heating Oil3.63+0.06
Natural Gas8.900.00

DOWNLOAD FREE REPORTS

×